NEW YORK ( TheStreet) -- CHANGE IN RATINGS, EPSAccretive Health ( AH) upgraded at Goldman from Neutral to Buy. $31 price target. Stock is attractive, following a 38% selloff. Acme Packet ( APKT) numbers reduced at Goldman. Shares of APKT now seen reaching $35, according to Goldman Sachs. Estimates also cut, given slower expected revenue growth. Neutral rating. Alaska Air ( ALK) numbers raised at Citigroup. Shares of ALK now seen reaching $81. Estimates also increased leading fundamentals and attractive valuation. Buy rating. Alaska Air estimates raised at UBS through 2012. Solid 3Q and 2012 cost guidance positive. Maintain $81 price target and Buy rating. Alexion Pharmaceuticals ( ALXN) numbers upped at Jefferies. ALXN estimates were boosted through 2012. Company is seeing higher Soliris sales and cutting costs. Hold rating and new $58 price target. Alexion Pharmaceutical estimates, target raised at UBS. Shares of ALXN now seen reaching $70. Estimates also increased on aHUS and margins. Neutral rating. Alliance Data Systems ( ADS) upgraded to buy at TheStreet Ratings. Altera ( ALTR) estimates, target reduced at Jefferies. ALTR estimates were cut through 2012. Inventories are falling. Buy rating and new $43 price target. Altera estimates, target cut at UBS. Shares of ALTR now seen reaching $44.50. Estimates also lowered as weak macro slows secular growth. Buy rating. Associated Banc-Corp ( ASBC) numbers lowered at Jefferies. Shares of ASBC now seen reaching $11. Estimates also cut, given reduced net interest income expectations. Buy rating. AT&T ( T) estimates lowered at Citigroup through 2012. Reflects an elevation in dilution from a rapid adoption of Smartphones. Maintain $32 price target and Buy rating. AutoNation ( AN) estimates, target raised at Goldman. Shares of AN now seen reaching $34. Estimates also increased, given better realized operating margin. Sell rating. AutoNation estimates lowered at UBS through 2011. Margins tailwinds end post Q3. Maintain $30 price target and Sell rating. Baxter ( BAX) estimates, target reduced at Goldman. BAX estimates were cut through 2014. Lower sales are hurting margins. Buy rating and new $66 price target. Blackstone ( BX) estimates adjusted at Citigroup through 2012. Reflects the 3Q shortfall, but also stronger long term asset gathering outlook. Maintain $18 price target and Buy rating. Capital One ( COF) numbers increased at Goldman through 2013. Higher revenue is driving margin expansion. Neutral rating and new $51 price target.